Brookmont Capital Management Has $3.68 Million Stock Position in AstraZeneca PLC $AZN

Brookmont Capital Management decreased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 2.4% in the second quarter, Holdings Channel.com reports. The firm owned 52,645 shares of the company’s stock after selling 1,267 shares during the period. AstraZeneca comprises 2.1% of Brookmont Capital Management’s holdings, making the stock its 14th largest holding. Brookmont Capital Management’s holdings in AstraZeneca were worth $3,679,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the company. Pure Financial Advisors LLC acquired a new stake in AstraZeneca during the second quarter valued at $225,000. Bartlett & CO. Wealth Management LLC raised its holdings in AstraZeneca by 46.2% during the second quarter. Bartlett & CO. Wealth Management LLC now owns 2,267 shares of the company’s stock valued at $158,000 after buying an additional 716 shares in the last quarter. Impact Capital Partners LLC raised its holdings in AstraZeneca by 15.6% during the second quarter. Impact Capital Partners LLC now owns 3,282 shares of the company’s stock valued at $229,000 after buying an additional 444 shares in the last quarter. Community Bank & Trust Waco Texas raised its holdings in AstraZeneca by 4.7% during the second quarter. Community Bank & Trust Waco Texas now owns 7,982 shares of the company’s stock valued at $558,000 after buying an additional 359 shares in the last quarter. Finally, PFG Investments LLC raised its holdings in AstraZeneca by 14.7% during the second quarter. PFG Investments LLC now owns 5,169 shares of the company’s stock valued at $361,000 after buying an additional 664 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Trading Up 10.0%

AstraZeneca stock opened at $84.36 on Thursday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.67 and a current ratio of 0.86. The business’s 50-day simple moving average is $77.59 and its 200-day simple moving average is $73.00. The firm has a market capitalization of $261.63 billion, a PE ratio of 31.71, a PEG ratio of 1.41 and a beta of 0.36. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $84.61.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 EPS for the quarter, hitting analysts’ consensus estimates of $1.09. The business had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.08 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The firm’s revenue for the quarter was up 16.1% on a year-over-year basis. During the same period in the previous year, the company posted $1.24 earnings per share. Equities research analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Monday, September 8th. Stockholders of record on Friday, August 8th were paid a $0.505 dividend. The ex-dividend date was Friday, August 8th. This represents a dividend yield of 200.0%. AstraZeneca’s payout ratio is presently 37.97%.

Wall Street Analyst Weigh In

Separately, Berenberg Bank set a $97.00 target price on AstraZeneca in a report on Wednesday, July 9th. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, AstraZeneca presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.